Form 4: Ionis Pharma CSO Reports Equity Transactions, New Grants

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, reported routine equity transactions including RSU vesting, a tax-related stock sale, and new performance and restricted stock unit grants.

Summary

• C. Frank Bennett, EVP, Chief Scientific Officer of Ionis Pharmaceuticals, Inc. (IONS), reported several equity transactions.
• On January 15, 2026, 21,055 shares of Common Stock were acquired due to the vesting and release of Restricted Stock Unit (RSU) awards.
• Following this acquisition, Mr. Bennett beneficially owned 103,734 shares of Common Stock.
• On January 16, 2026, 8,977 shares of Common Stock were disposed of at a weighted average price of $75.15 per share to cover required tax withholding obligations related to the RSU vesting.
• After the sale, Mr. Bennett's direct beneficial ownership of Common Stock was 94,757 shares.
• On January 15, 2026, Mr. Bennett was granted 25,800 Performance Restricted Stock Units (PRSUs) under the 2011 Equity Incentive Plan, which may vest based on the Issuer's relative total shareholder return over a three-year period.
• Also on January 15, 2026, Mr. Bennett was granted 9,675 Restricted Stock Units (RSUs) under the 2011 Equity Incentive Plan, which vest in four equal annual installments.
• The number of PRSUs reported represents the maximum that may be earned (200% of target), with actual vesting ranging from zero to the stated amount.

Sentiment

Score: 6

Explanation: The filing reflects routine executive compensation activities, including new grants that align management with long-term performance, which is generally positive. The sale of shares for tax purposes is neutral and expected.

Positives

• The grant of 25,800 Performance Restricted Stock Units (PRSUs) and 9,675 Restricted Stock Units (RSUs) aligns the Chief Scientific Officer's incentives with the company's long-term performance and shareholder value.
• The PRSUs are performance-based, contingent on the company's relative total shareholder return, indicating a focus on achieving competitive market performance.

Negatives

• A sale of 8,977 shares of Common Stock, even for tax withholding purposes, reduces the direct beneficial ownership of the executive.

Risks

• The vesting of the 25,800 Performance Restricted Stock Units (PRSUs) is contingent on Ionis Pharmaceuticals' relative total shareholder return compared to a peer group over a three-year performance period, meaning the actual number of shares that will vest could range from zero to the maximum stated amount.
• The value of the RSU and PRSU awards is subject to the future market price of Ionis Pharmaceuticals' common stock.

Future Outlook

The future compensation for the Chief Scientific Officer, particularly regarding the Performance Restricted Stock Units, is tied to Ionis Pharmaceuticals' relative total shareholder return over the next three years, indicating a forward-looking incentive structure aimed at enhancing shareholder value.

Industry Context

Executive equity compensation, including restricted stock units and performance-based awards, is a standard practice across the biotechnology and pharmaceutical industries. This approach aims to align management incentives with long-term company performance and shareholder value, a common strategy for talent retention and motivation in competitive sectors.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Restricted Stock Units (PRSUs) as a component of executive compensation is a widely adopted practice in the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Biogen, Gilead Sciences, or Amgen.
• The structure of PRSUs, contingent on relative total shareholder return against a peer group, is a common mechanism to incentivize outperformance within the industry, similar to performance metrics used by many S&P 500 companies for their executive long-term incentive plans.

Corporate Governance

Related Party Transactions

• The acquisition of shares through RSU vesting and the grant of new PRSUs and RSUs represent compensation transactions between the company and a key executive, C. Frank Bennett.

Stakeholder Impact

• Shareholders: The new performance-based equity grants aim to align executive incentives with shareholder returns, potentially benefiting long-term shareholder value. However, future vesting could lead to minor dilution.
• Employees (Executive): C. Frank Bennett's compensation package is enhanced with new equity awards, providing long-term incentives tied to company performance.

Next Steps

• The 9,675 Restricted Stock Units will vest in four equal annual installments, with the first installment expected on January 15, 2027.
• The 25,800 Performance Restricted Stock Units will be evaluated for vesting at the end of a three-year performance period, concluding on January 15, 2029, based on the company's relative total shareholder return.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Restricted Stock Units, Performance Restricted Stock Units, Equity Incentive Plan, Executive Compensation, Stock Transactions, Beneficial Ownership